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Background: Bronchopulmonary dysplasia (BPD) is the most common complication of
very preterm birth and can lead to lifelong health consequences. Optimal nutrition is a
cornerstone in the prevention and treatment of BPD. In very preterm infants, mother’s
own milk (MOM) feeding is associated with lower risks of necrotizing enterocolitis,
retinopathy of prematurity, and sepsis. Although several studies have shown that MOM
may protect against BPD, a systematic analysis of the evidence has not been performed
to date.
Methods: A comprehensive literature search was conducted using PubMed/MEDLINE
and EMBASE, from their inception to 1 December 2017. Longitudinal studies comparing
the incidence of BPD in preterm infants fed with exclusive MOM, MOM supplemented
with preterm formula (PF), and/or exclusively fed with PF were selected. A random-effects
model was used to calculate the Mantel Haenszel risk ratio (RR) and 95% confidence
interval (CI).
Results: Fifteen studies met the inclusion criteria (4,984 infants, 1,416 BPD cases).
Use of exclusive MOM feedings was associated with a significant reduction in the risk
of BPD (RR 0.74, 95% CI 0.57–0.96, 5 studies). In contrast, meta-analysis could not
demonstrate a significant effect on BPD risk when infants fed with more than 50% MOM
were compared with infants fed with <50% MOM (RR 0.98, 95% CI 0.77–1.23, 10
studies) or when infants fedwithMOM supplementedwith PFwere comparedwith infants
fed with exclusive PF (RR 1.00, 95% CI 0.78–1.27, 6 studies). Meta-regression showed
that differences in gestational age were a significant confounder of the effect of MOM.
Conclusion: To our knowledge, this is the first systematic review and meta-analysis
that specifically evaluates the role of MOM on BPD. Our data indicate that MOM may
reduce the incidence of BPD when used as an exclusive diet, but this result needs to
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be interpreted with caution. We did not find the same difference in analyses with other
dosages of MOM. Further studies adequately powered to detect changes in BPD rates
and that adjust for confounders are needed to confirm the beneficial effects of MOM
on BPD.
Keywords: mother’s own milk, human milk, bronchopulmonary dysplasia, preterm formula, meta-analysis,
systematic review, meta-regression
INTRODUCTION
Mother’s own milk (MOM), fresh or frozen, is the normative
standard for preterm infant feeding and nutrition (1–4). If MOM
is unavailable despite significant lactation support, pasteurized
donor human milk (DHM) is the recommended alternative
over the use of bovine milk-based preterm formula (PF) (1–
4). However, it is increasingly recognized that numerous MOM
components which could contribute to its protective effects
against adverse outcomes of prematurity are reduced or absent
in DHM (5).
Bronchopulmonary dysplasia (BPD) is one of the most
common complications of prematurity, and it predicts multiple
adverse outcomes including chronic respiratory impairment and
neurodevelopmental delay (6, 7). Optimal nutritional support is
considered a cornerstone in the treatment/prevention of BPD
(8). Recently, we performed a systematic review and meta-
analysis on the effects of DHM on BPD (9). Meta-analysis
of randomized controlled trials (RCTs) could not demonstrate
that supplementation of MOM with DHM had a significant
effect on BPD risk when compared to supplementation
with PF. However, meta-analysis of observational studies
showed a protective effect of DHM supplementation on
BPD (9). Two very recent systematic reviews confirmed that
the protective effects of human milk (i.e., MOM and/or
DHM) on BPD are only observed in meta-analysis of
observational studies (10, 11). Using the GRADE-system (12),
the authors of these meta-analyses consider the evidence to
be inconclusive.
Despite the important differences between DHM and MOM,
the umbrella term “humanmilk” is frequently used to encompass
both MOM and DHM, implying that the beneficial effects of
MOM can be directly extrapolated to DHM (5, 13). Moreover,
many of the studies and meta-analyses have compared PF
feedings with various combinations of PF, MOM, and DHM.
A recent meta-analysis evaluated the effects of MOM on
retinopathy of prematurity (ROP) (14). This analysis excluded
data on DHM and showed that the overall incidence of ROP
was reduced among infants fed MOM compared with those fed
PF. To the best of our knowledge, no systematic review has
focused on the role of MOM in the development of BPD. The
analysis of exclusive MOM vs. PF was beyond the scope of our
previous study (9), and Miller et al. and Huang et al. did not
study the effect of MOM separately from that of DHM (10, 11).
Therefore, we aimed to conduct a systematic review and meta-
analysis on the association between MOM/PF feeding and BPD
development. The present meta-analysis does not include data
on DHM.
METHODS
This study is a continuation of our previous review on DHM
and BPD (9), and shares much of the same methodology. We
expanded on the protocol of our earlier study, and specified the
objectives, criteria for study inclusion, method for evaluating
study quality, outcomes and statistical methodology. We report
this study according to the guidelines of the Preferred Reporting
Items for Systematic Reviews andMeta-Analysis (PRISMA) (15).
The PRISMA checklist for this report can be found in the
Supplementary Material.
Data Sources and Search Strategy
We modified and expanded on the search strategy of our earlier
review (9). We carried out a comprehensive literature search
using PubMed/Medline and EMBASE, from their inception
to March 1, 2018. The search strategy for PubMed used the
following terms, including Mesh terms: (breast milk OR infant
feeding OR mother’s own milk) AND (preterm infant OR very
low birth weight infant) AND (outcome OR bronchopulmonary
dysplasia OR BPD) AND (observational study OR cohort study
OR case-control). We used a similar strategy in EMBASE. We
applied no language restrictions. We translated articles when
needed. We included cohort and case-control studies in this
review, as well as RCTs with an observational arm. Other types of
studies were excluded, but when considered relevant, they were
read to identify additional studies to include. We also used the
“cited by” tool in Google Scholar and Web of Science to identify
studies for inclusion. Moreover, we included articles which we
came across in the elaboration of our earlier review (9).
Eligibility Criteria and Study Selection
We included studies if they were original cohort or case-control
studies, which examined very preterm (gestational age, GA <32
weeks) or very low birth weight (VLBW, BW <1,500 g) infants
receiving either MOM or PF, and which included at least two
groups divided according to feeding policy. Only full-length
published studies were considered for inclusion. Studies were
included if they reported results on the incidence of BPD. We
defined BPD as oxygen dependence at 28 days of life (BPD28)
or as oxygen dependence at 36 weeks adjusted gestational
age (BPD36). Studies were excluded if the group receiving
MOM or PF also received DHM. Two reviewers (EV-M, EV)
independently screened the results of the searches, and included
studies according to the inclusion criteria using EndNote
(RRID:SCR_014001), using the methodology of Bramer et al.
(16). Studies on which reviewers disagreed for inclusion were
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identified, and discrepancies were resolved through discussion or
by consulting the other authors.
Data Extraction
We collected the following information per study: citation
information, study design, number of patients, number of
centers, location of study, inclusion and exclusion criteria, patient
characteristics (GA, BW), type of feeding received (MOM,
PF, combination of MOM and PF, and type of fortifier), and
incidence of BPD per group. Two researchers (EV-M, EV)
extracted the data using an Excel sheet designed for this review.
We resolved discrepancies in data extraction through discussion,
or by consulting the other authors. Another researcher (MP)
independently validated the accuracy of the data extracted.
Assessment Risk of Bias
Two researchers (EV-M, MP) assessed the risk of bias in included
studies. We used the Newcastle-Ottawa Scale (NOS) for quality
assessment of cohort and case-control studies. The NOS is
used to assign a score to studies on selection (0–4 points),
comparability (0–2 points), and outcome/exposure (0–3 points),
for a total score of up to 9 points. Discrepancies were resolved
through discussion.
Statistical Analysis
We used Comprehensive Meta-Analysis V3.0 software
(RRID:SCR_012779) to combine and analyze studies. The
Mantel Haenszel (MH) risk ratio (RR) for BPD with 95%
confidence interval (CI) was calculated in each study. Due to
anticipated heterogeneity, we used a random-effects model to
combine studies. This model accounts for heterogeneity between
and within studies and it does not assume that “true” effect sizes
are identical across studies. Subgroup analyses were conducted
according to the mixed-effects model (17). In this model a
random-effects analysis is used to combine studies within each
subgroup, and a fixed-effect model is used to combine subgroups
and yield the overall effect. The model does not assume study-
to-study variance (tau-squared) to be the same for all subgroups.
We assessed statistical heterogeneity using the Cochran’s Q
statistic, and the I2 statistic which is derived from it. We planned
to evaluate the risk of publication bias through visual inspection
of the funnel plot and with Egger’s regression test (18). We
decided a priori to analyze the effect of GA as a confounding
factor, by analyzing the mean difference in this covariate between
groups, and through subgroup analysis, by removing studies
with large differences in GA from analysis. We decided to use
the group with the higher MOM intake as the reference group in
all our analyses. We carried out sensitivity analyses by removing
one study from analyses at a time. We used an α = 0.05 for
statistical significance (α = 0.10 for statistical heterogeneity).
RESULTS
After removing duplicates, our comprehensive search found 965
articles, of which we identified 84 as potentially relevant, and
15 met our inclusion criteria (19–33) after full-text review. The
PRISMA search diagram is shown in Figure 1. The characteristics
of the included studies are shown in Supplementary Table 1.
Fourteen included studies were observational cohorts, of which
seven were prospective (20, 21, 23, 25, 30, 31, 33) and seven
were retrospective (19, 22, 24, 26, 28, 29, 32), and one study was
a retrospective case-control (27). One study was excluded from
meta-analysis because it did not group by type of feeding (22).
We divided studies according to the proportion of feeding that
was MOM or PF in each group, and we made three comparisons
for analysis: (1) Exclusive MOM vs. Any PF; (2) Mainly MOM vs.
Mainly PF; (3) Any MOM vs. Exclusive PF.
Quality Assessment
Three studies scored six points on the NOS, 10 studies scored
seven points, and two studies scored the maximum of 9
points. We downgraded studies in quality for not adjusting for
confounders (k = 13), for excluding infants who were lost to
follow-up (k= 2) and for not defining BPD clearly (k= 1).
Exclusive MOM vs. Any PF
Five studies (19–21, 27, 30) compared infants who received a
diet of exclusive MOM to infants who received MOM and any
supplementation with PF. Meta-analysis of these studies found
that the exclusive MOM group had a reduced risk of BPD (RR
0.74, 95% CI 0.57–0.96, p = 0.021, Figure 2). When we excluded
the study of Fewtrell et al. which used a different definition of
BPD (BPD28), the effect of MOM on BPD remained significant
(RR 0.71, 95% CI 0.54–0.93 p = 0.014). Sensitivity analysis
showed that removing the study of Madore et al. (27) or the study
of Schanler et al. (30) made the overall association no longer
significant (Supplementary Figure 1).
When we analyzed the difference in GA between groups,
meta-analysis did not find a significant difference (MDGA−0.06
weeks, 95% CI−0.38–0.25, p= 0.689, Supplementary Figure 2).
None of the included studies had a mean difference in GA
between groups which was larger than 0.3 weeks.
Out of the five studies which had an exclusive MOM group,
three studies (19–21) also provided data on a group of infants
receiving exclusive PF. We carried out a subgroup analysis of
these studies. When pooled, meta-analysis could not find a
significant difference in BPD risk between groups (RR 1.08, 95%
CI 0.63–1.87, p = 0.770 Figure 3). When we excluded the study
of Fewtrell et al., which defined BPD as BPD28 instead of BPD36,
the effect of MOM did not change in significance (RR 1.10,
95% CI 0.58–2.09, p = 0.777). When we removed the study of
Assad et al. for having a MD in GA (of 1.5 weeks) between
groups ≥0.5 weeks, the results did not change in significance
(RR 0.88, 95% CI 0.57–1.37, p = 0.583). An analysis on the
difference in GA between groups did not find a significant
difference overall (MD −0.41 weeks, 95% CI −1.19–0.36, p =
0.295, Supplementary Figure 3).
Mainly MOM vs. Mainly PF
Ten studies compared infants receiving mainly MOM vs. infants
receiving mainly PF. We included studies which had stricter
criteria for comparison (i.e., exclusive MOM vs. exclusive PF) in
this analysis as well. Meta-analysis could not find a significant
difference in risk of BPD between the mainly MOM and the
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FIGURE 1 | PRISMA diagram of the search.
mainly PF group (RR 0.98, 95% CI 0.77–1.23, p = 0.833,
Figure 4). When we excluded the study of O’Connor et al. for
using a definition of BPD at 28 days of life instead of at 36 weeks
PMA, the effect of MOM on BPD development remained non-
significant (RR 0.99, 95% CI 0.75–1.31, p= 0.938). Excluding any
study one at a time did not change the significance of the effect of
MOM on BPD (Supplementary Figure 4).
We used meta-analysis to study the differences in GA
between the MOM and PF groups in each study. Meta-
analysis found no significant MD in GA when pooling all
studies together (MD −0.31 weeks, 95% CI −0.78–0.17, p =
0.204, Supplementary Figure 5). However, individual studies
showed significant differences in GA between groups, and the
heterogeneity was very high (p < 0.001, I2 = 92.1%), which
indicated that GA could be a significant confounder. When we
used subgroup analysis to exclude studies where the difference
in GA between groups was larger than 0.5 weeks, we were left
with 6 studies, but the effect of MOM on BPD did not change
significantly (RR 0.99, 95% CI 0.82–1.18, p= 0.890).
We used meta-regression to explore the role of GA in
potentially modifying the effect of MOM on BPD development.
Meta-regression found a significant association between MD in
GA and the risk of BPD in the MOM group (Coefficient: −0.59,
95% CI −0.95 to −0.23, p = 0.001, R2 = 1.00, Figure 5). This
indicates that in studies where the MOM group had a higher risk
of BPD, this group was also more premature than the PF group,
and in studies where the MOM group had a lower risk of BPD,
this group was also more mature than the PF group.
Any MOM vs. Exclusive PF
Six studies (19, 20, 23–25, 33) compared infants who received any
MOM to infants who received exclusive PF. We also included
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FIGURE 2 | Meta-analysis of exclusive MOM vs. any PF and risk of BPD. MOM, mother’s own milk; PF, preterm formula; BPD, bronchopulmonary dysplasia; CI,
confidence interval; MH, Mantel-Haenszel.
FIGURE 3 | Meta-analysis of exclusive MOM vs. exclusive PF and risk of BPD. MOM, mother’s own milk; PF, preterm formula; BPD, bronchopulmonary dysplasia; CI,
confidence interval; MH, Mantel-Haenszel.
FIGURE 4 | Meta-analysis of mainly MOM vs. mainly PF and risk of BPD. MOM, mother’s own milk; PF, preterm formula; BPD, bronchopulmonary dysplasia; CI,
confidence interval; MH, Mantel-Haenszel.
Frontiers in Pediatrics | www.frontiersin.org 5 June 2019 | Volume 7 | Article 224
Villamor-Martínez et al. Mother’s Own Milk and Bronchopulmonary Dysplasia
FIGURE 5 | Meta-regression of MD in GA between the MOM and PF group,
and risk of BPD. CI, confidence interval; BPD, bronchopulmonary dysplasia.
studies in this comparison where the infants of the MOM group
received larger proportions of MOM (e.g., infants receiving
mainly MOM or exclusive MOM). Meta-analysis could not find a
significant effect of any MOM on the risk of developing BPD (RR
1.00, 95% CI 0.78–1.27, p = 0.975, Figure 6). When we removed
the study of Hylander et al. from the analysis, which did not
clarify their definition of BPD, the effect of any MOM remained
non-significant (RR 1.07, 95% CI 0.80–1.42, p= 0.665). Removal
of any one study did not affect the significance of the results
(Supplementary Figure 6).
Meta-analysis found that there was a significant difference in
mean GA between the any MOM group and the exclusive PF
group, with the infants receiving any MOM being born earlier
(MD−0.50 weeks, 95% CI−0.99 to−0.01, p= 0.045, Figure 7).
Removing studies where the groups differed by more than 0.5
weeks in GA left us with three studies (20, 24, 33), but the effect
of MOM on BPD remained non-significant (RR 0.93, 95% CI
0.82–1.05, p= 0.236, Supplementary Figure 7).
Publication Bias
We tested the three comparisons for publication bias
(Supplementary Figure 8), but neither visual inspection of
the funnel plot nor Egger’s regression test could find significant
evidence of publication bias. A small number of studies made the
analyses on “Exclusive MOM vs. Any PF” and “Any MOM vs.
Exclusive PF” inconclusive (Supplementary Figure 8).
Adjusted Data
Two studies (23, 26) reported data on BPD incidence that was
adjusted for confounders. Furman et al. (23) reported incidence
of BPD by amount of maternal milk received, and they adjusted
for several confounders (BW, sex, and ethnicity). They found
no significant difference in BPD risk for varying levels of MOM
intake, compared to receiving exclusive PF. Maayan-Metzger
et al. (26) used logistic regression to adjust for confounders
including GA, BW and sex. They found that receiving only or
mainly MOM, compared to receiving only or mainly PF, did not
significantly affect the risk of developing BPD. They found the
same result in the subgroup of infants with GA 24–28 weeks.
Other Studies
One study (22) did not group according to MOM or PF intake.
Instead they compared infants with BPD to infants without BPD
and studied median intake of MOM in the first 6 weeks of life.
In their study infants were given MOM, supplemented by PF
when necessary. They found infants with BPD had a significantly
lower median daily MOM intake compared to infants without
BPD (2.3 mL/kg/d vs. 10.8). The protective effect on BPD of a
higher MOM intake at 42 days remained after adjustment for
confounding factors (RR 0.98, 95% CI 0.96–0.99, p= 0.030).
DISCUSSION
RCTs are widely regarded to provide the highest degree of
evidence (34). However, the random allocation of infants to a
group receiving PF instead of MOM is not ethical and, therefore,
evidence must be based on observational studies (14, 35). To our
knowledge, this is the first systematic review and meta-analysis
that specifically evaluated the role of MOM on BPD. We found
that MOM reduced the risk of developing BPD but only when
used as an exclusive diet. In contrast, meta-analysis could not
find significant changes in BPD risk when comparing infants
fed mainly with MOM with those fed mainly with PF, or when
comparing any MOM vs. exclusive PF.
The reduction of BPD rates whenMOM is used as an exclusive
diet may have various explanations. The major pathogenetic clue
of BPD is the arrest in the alveologenesis and vasculogenesis
of the lung due to very preterm birth (36). Superimposed
inflammatory events complete this detrimental picture (37, 38).
Prenatally, in the setting of chorioamnionitis, the overwhelming
inflammatory cascade may interfere with lung development
(37). Postnatally, the intensive care support needed by very
preterm infants, including resuscitation, mechanical ventilation,
and oxygen administration, carries a high grade of inflammation
to the immature lung, leading to the establishment of BPD (38).
When postnatal infections occur, the incidence of BPD sharply
increases (39–41). Finally, inadequate nutrition can further
worsen BPD (42).MOMmay reduce the incidence of BPD thanks
to nutritional and bioactive components, counteracting oxidative
stress (43), inflammation (44, 45), and nutritional flaws involved
in the BPD pathogenesis (46, 47). In addition, MOM may also
impact the risk of BPD indirectly by reducing the incidence of
necrotizing enterocolitis (NEC) and late-onset sepsis (LOS).
Due to the observational character of the studies included
in the meta-analysis, the MOM and PF groups may differ
in a number of maternal and infant characteristics which
may affect the development of BPD. Previous studies
have shown associations between characteristics such as
ethnicity, socioeconomic status, maternal education, pregnancy
hypertensive disorders, smoking during pregnancy, GA, BW,
infant sex, Apgar score, or respiratory distress syndrome, and
rate of MOM feeding in preterm infants (32, 48–54). We
evaluated one possible major confounder: difference in GA
between groups. GA played a role in modifying the association
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FIGURE 6 | Meta-analysis of Any MOM vs. Exclusive PF and risk of BPD. MOM, mother’s own milk; PF, preterm formula; BPD, bronchopulmonary dysplasia; CI,
confidence interval; MH, Mantel-Haenszel.
FIGURE 7 | Meta-analysis of Any MOM vs. Exclusive PF, mean difference (MD) in gestational age (GA) between groups. MOM, mother’s own milk; PF, preterm formula.
between MOM and BPD, as we have shown through meta-
regression and sub-group analyses. This is relevant since the
incidence of all the complications of prematurity, including
NEC, LOS, and BPD, is inversely related to GA. In studies which
compared mainly MOM vs. mainly PF, the comparison that
included the highest number of studies, meta-regression showed
a significant correlation between difference in GA and the
protective effect of MOM on BPD (Figure 5). In other words, in
the studies where the mainly MOM group had a higher BPD risk,
this group was also more premature than the mainly PF group.
Interestingly, in the comparison where we found a significant
positive result (exclusive MOM vs. any PF), the differences in
GA between groups were small. This suggests that the protective
effects of exclusive MOM are not affected by GA as confounder
in this analysis.
Several studies have reported that the effects of human milk
in reducing the incidence of adverse outcomes of prematurity are
dose-dependent (14, 23, 31, 55–58). It has been suggested that at
least 50% of the infant’s total enteral intake should be MOM in
order to achieve a decreased incidence of NEC (13). With regards
to BPD, Patel et al. have shown a 9.5% reduction in the risk of
BPD for each 10% increase in MOM received from birth to 36
weeks PMA. This may generate a reduction in BPD risk up to
63% when an exclusive MOM diet is compared with an exclusive
PF diet (55). Surprisingly, the present meta-analysis could not
demonstrate a different rate of BPD in infants fed exclusiveMOM
when compared with infants fed exclusive PF. However, this
analysis was based on only three studies (Figure 3). Moreover,
in one of the studies the infants in the PF group had a markedly
higher GA (1.5 weeks) than the infants of the MOM group. To
date, there are no exact limits set in the amount of MOM that
would produce benefits in terms of BPD reduction (59). The
studies that we analyzed documented a high variability of MOM
amount in their study groups. Since the relation between MOM
and BPD, may not be as direct as for NEC and LOS, it is possible
that higher minimum amounts of MOMmay be needed to detect
significant differences. In addition, the conditions of storage and
the use of fresh, refrigerated, frozen, or deep-frozen MOM may
affect the antioxidant as well as other biological properties of
MOM (60).
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CONCLUSION
Our data indicate that MOM may reduce the incidence of BPD
when used as an exclusive diet, but this result needs to be
interpreted with caution. We did not find the same difference in
analyses with other dosages of MOM, whichmay be related to the
high variability in the available studies and the dose-dependent
beneficial effects of MOM. It may also be due to differences
in GA between infants who receive MOM and infants who
receive PF, which we found had modified the protective effects
of MOM against BPD. Moreover, there may be other differences
in infant and maternal characteristics that play a role and which
we could not account for. Further studies, adequately powered
to detect changes in BPD rates, and that adjust for the different
characteristics of infants who receive MOM and PF are needed to
confirm the beneficial effects of MOM on BPD.
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